Tramadol News and Research

RSS

ARRA stimulus funds fuel research projects across America

The Association of American Universities (AAU), the Association of Public and Land-grant Universities (APLU), and The Science Coalition (TSC) today released highlighted examples of the important scientific work happening across the country as a result of the American Recovery and Reinvestment Act of 2009 (ARRA). The brief report summarizes just a handful of the thousands of projects benefiting from stimulus dollars.

30 Sep 2009

Labopharm to present its novel trazodone formulation data

Labopharm Inc. today announced that three separate posters will be presented at three upcoming internationally prestigious medical meetings showcasing data on its novel trazodone formulation.

10 Sep 2009

FDA accepts Labopharm's response for its novel trazodone formulation

Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced the U.S. Food and Drug Administration (FDA) has accepted Labopharm's response regarding its novel formulation of the antidepressant trazodone as complete and designated it as a Class 2 resubmission. The FDA has assigned Labopharm a new Prescription Drug User Fee Act (PDUFA) action date of February 11, 2010.

26 Aug 2009

Labopharm comments on outcome of patent-infringement litigation initiated by Purdue Pharma

Labopharm Inc. today commented on the outcome of patent-infringement litigation initiated by Purdue Pharma Products L.P. against Par Pharmaceutical Companies, Inc. relating to Ultram(R) ER (tramadol hydrochloride extended-release tablets). The patents-in-suit are owned by Purdue and are licensed to Ortho-McNeil, Inc., the marketer of Ultram(R) ER.

18 Aug 2009

Par Pharmaceutical wins in Ultram ER litigation

Par Pharmaceutical Companies, Inc. today announced that the U.S. District Court for the District of Delaware has ruled in favor of Par in its challenge of Purdue's patents relating to extended-release tramadol, which are listed in the Orange Book for Ortho-McNeil's Ultram(R) ER product.

18 Aug 2009

Labopharm comments on outcome of patent-infringement litigation initiated by Purdue Pharma

17 Aug 2009

Codeine users more at risk for traffic accidents

The risk of being involved in a traffic accident with personal injury is significantly higher among codeine users than non-users.

24 Mar 2009

Savella - Fibromyalgia treatment approved by FDA

Forest Laboratories, Inc. and Cypress Bioscience, Inc. have announced that Savella (milnacipran HCl), a selective serotonin and norepinephrine dual reuptake inhibitor, was approved by the U.S. Food and Drug Administration (FDA) for the management of fibromyalgia.

19 Jan 2009

IMPAX sued for patent infringement on generic Ultram ER

IMPAX Laboratories, Inc. today announced Purdue Pharma Products L.P. ("Purdue"), Napp Pharmaceutical Group Ltd. ("Napp"), Biovail Laboratories International, SRL ("Biovail") and Ortho-McNeil, Inc. ("Ortho-McNeil") have filed suit for patent infringement in the United States District Court for the District of Delaware based on the Company's submission of its Abbreviated New Drug Application ("ANDA") for tramadol hydrochloride extended-release tablets (100 mg), generic of Ultram ER, to the Food and Drug Administration.

12 Aug 2008

Ortho-McNeil settles patent cases against Par/Kali

Ortho-McNeil, Inc. has announced that it settled its patent litigation against Par Pharmaceutical Companies, Inc. and its subsidiaries, Par Pharmaceutical, Inc., and Kali Laboratories, Inc., generic drug manufacturers, regarding their infringement of the Ortho-McNeil patent for ULTRACET (tramadol/acetaminophen).

20 Jul 2007

All pain medications may raise risk of heart attack or stroke

Not long ago, choosing a pain reliever meant finding one that eased your pain without being too hard on the stomach.

1 Jun 2007

International expert group discusses alternatives to COX-2 inhibitors

International group of pain specialists meets to develop recommendations for the treatment of chronic moderate-to-severe pain in the wake of the global withdrawal of rofecoxib (Vioxx) and concerns regarding use of other COX-2 inhibitors.

7 Mar 2005

ULTRACET® Effective And Well Tolerated For Post-Surgical Pain

A new study published in the latest edition of a leading medical journal has shown that treatment with ULTRACET® (37.5 mg tramadol hydrochloride/325 mg acetaminophen tablets) demonstrates similar efficacy and better tolerability than TYLENOL® with Codeine No. 3 when each is compared to placebo.

5 Apr 2004